Zepbound® vs. Mounjaro®: Same Drug, Different Uses

Zepbound® and Mounjaro® hold the same drug, tirzepatide, but carry different FDA approvals, so the brand you get follows your diagnosis ^{[1, 2]}. Both labels were revised in August 2026, and Mounjaro® now has two uses most comparisons miss.

Read on for approved uses, dosing, trial results, side effects, Medicare coverage, and which brand fits which situation.

Are Zepbound® and Mounjaro® the same drug?

Yes, Zepbound® and Mounjaro® are the same drug. Both contain tirzepatide and are made by Eli Lilly, the labels show ^{[1, 2]}. Lilly sells one molecule under two brand names because each brand carries a different set of FDA-approved uses.

Tirzepatide is a once-weekly injection that activates two gut-hormone receptors, GIP and GLP-1 ^{[1, 2]}. GIP stands for glucose-dependent insulinotropic polypeptide, and GLP-1 stands for glucagon-like peptide-1. Acting on both helps release insulin when blood sugar rises, slows stomach emptying and reduces appetite.

The FDA approved tirzepatide first as Mounjaro® on May 13, 2022, for type 2 diabetes ^[3]. It approved the same drug as Zepbound® on November 8, 2023, for chronic weight management ^[4]. That is why both labels list "Initial U.S. Approval: 2022" ^{[1, 2]}.

Quick verdict: Neither brand is stronger, because the medicine inside is identical. If your main diagnosis is type 2 diabetes, Mounjaro® is the brand approved for you. If your goal is weight reduction or sleep apnea without diabetes, Zepbound® carries those approvals.

Novo Nordisk uses the same two-brand approach with semaglutide. Ozempic® (semaglutide) is approved for type 2 diabetes, and Wegovy® (semaglutide) is approved for weight management. See our Wegovy® vs. Ozempic® comparison [LINK: verify live].

How do Zepbound® and Mounjaro® compare at a glance?

Zepbound® and Mounjaro® differ in approved uses, approved ages and maintenance-dose rules, not in what's inside ^{[1, 2]}. Everything else, from strengths to the boxed warning, matches.

Table: Zepbound® vs. Mounjaro® at a glance. Source: Zepbound® and Mounjaro® Prescribing Information, both revised 08/2026 ^{[1, 2]}; FDA press releases ^{[3, 4]}.

[COMMERCIAL MODULE: /compare/ pick block, condition-matched. CTA copy: "See if you qualify for tirzepatide." Theme-managed. No prices. Affiliate disclosure theme-injected.]

What is each brand FDA-approved to treat?

Zepbound® is approved for weight and sleep apnea, while Mounjaro® is approved for type 2 diabetes and heart-risk reduction ^{[1, 2]}. Neither brand is approved for the other brand's uses.

Table: FDA-approved uses by brand. Source: Zepbound® and Mounjaro® Prescribing Information, Indications and Recent Major Changes ^{[1, 2]}; FDA press releases ^{[3, 4, 5]}.

Weight reduction (Zepbound®): The FDA's 2023 approval defined obesity as a BMI of 30 or higher ^[4]. Overweight meant a BMI of 27 or higher with a weight-related condition, such as high blood pressure.

Sleep apnea (Zepbound®): Obstructive sleep apnea (OSA) is breathing that stops and starts during sleep. The FDA called Zepbound® the first drug treatment for OSA when it approved this use on December 20, 2024 ^[5].

Children (Mounjaro® only): Zepbound®'s label says its safety and effectiveness in children have not been established ^[1]. Mounjaro® is the only tirzepatide brand approved for anyone under 18, and only for type 2 diabetes ^[2].

Are Zepbound® and Mounjaro® doses the same?

Yes, Zepbound® and Mounjaro® come in the same strengths and both start at 2.5 mg once a week ^{[1, 2]}. The labels differ in how a maintenance dose is chosen.

Table: Dosing by brand and use. Source: Zepbound® Prescribing Information, sections 2.1 to 2.3 ^[1]; Mounjaro® Prescribing Information, section 2.1 ^[2].

The 2.5 mg dose is for starting only, not for staying on, the Zepbound® label says ^[1]. Both labels allow you to change your injection day if at least 3 days (72 hours) pass between doses ^{[1, 2]}.

Your prescriber sets and adjusts your dose. Don't change it on your own, even if someone on the other brand takes a different dose.

What forms do Zepbound® and Mounjaro® come in?

Zepbound® and Mounjaro® each come in four forms: single-dose pens, single-dose vials, multi-dose vials and KwikPens ^{[1, 2]}. Each multi-dose vial and each KwikPen holds 4 weekly doses.

Table: Zepbound® and Mounjaro® forms. Source: Zepbound® and Mounjaro® Prescribing Information, sections 2, 3 and 5.10 ^{[1, 2]}.

Mounjaro®'s label adds that children should not inject themselves with the KwikPen ^[2].

How common are dosing mistakes with these drugs?

Dosing mistakes are the most-reported problem for both brands in the FDA Adverse Event Reporting System (FAERS) ^[14]. "Incorrect dose administered" tops the list for Zepbound® and Mounjaro® alike.

Table: Top FAERS report terms by brand. Source: openFDA drug adverse event API, brand names Zepbound® and Mounjaro®, data last updated July 30, 2026, queried October 2, 2026 ^[14]. A report can list more than one term.

FAERS reports are voluntary and don't prove the drug caused a problem. Report counts also can't be compared as rates, because the number of people using each brand differs.

The pattern is still useful. If your form or strength changes, for example from a pen to a vial, ask for training before your next dose ^{[1, 2]}.

Does Zepbound® or Mounjaro® work better?

Neither brand works better, because the drug and doses are the same. Their trials measured different outcomes in different people, so the results can't be ranked against each other.

Table: Key tirzepatide trials by brand. Sources: Jastreboff and others 2022 ^[6]; Garvey and others 2023 ^[7]; Malhotra and others 2024 ^[8]; Frías and others 2021 ^[9]; Mounjaro® Prescribing Information, section 14.5 ^[2]; Nicholls and others 2025 ^[10].

Weight loss: Zepbound® trials

Zepbound® led to 15.0% to 20.9% average weight loss over 72 weeks in adults without diabetes, depending on dose ^[6]. In the SURMOUNT-1 trial of 2,539 adults, people on placebo lost 3.1% ^[6].

Weight loss was smaller in people with type 2 diabetes. In the SURMOUNT-2 trial of 938 adults, people lost 12.8% and 14.7% on 10 and 15 mg over 72 weeks ^[7].

Stopping the drug matters too. In a trial of 670 adults, everyone first took Zepbound® for 36 weeks and lost an average of 20.9% ^[1]. Over the next 52 weeks, people switched to placebo regained 14.0%, while those who stayed on lost a further 5.5% ^[1].

Sleep apnea: Zepbound® trials

Zepbound® cut breathing interruptions by about 25 to 29 events per hour over 52 weeks in the SURMOUNT-OSA trials of 469 adults ^[8]. Average starting levels were about 50 events per hour.

In people not using a CPAP machine, interruptions fell 25.3 per hour on tirzepatide vs. 5.3 on placebo ^[8]. In people using CPAP, they fell 29.3 vs. 5.5 ^[8].

Blood sugar and heart events: Mounjaro® trials

Mounjaro® lowered A1C, a 3-month blood sugar average, by 2.01 to 2.30 points over 40 weeks in the SURPASS-2 trial of 1,879 adults ^[9]. People on Ozempic® (semaglutide) 1 mg had a 1.86-point drop, and tirzepatide was superior at every dose ^[9].

In children, the SURPASS-PEDS trial of 99 children and teens 10 and older found A1C fell 2.0 points over 30 weeks, vs. 0.2 on placebo ^[2].

For heart events, the SURPASS-CVOT trial followed 13,299 adults with type 2 diabetes and heart or blood vessel disease for a median of about 4 years ^[10]. It compared tirzepatide with Trulicity® (dulaglutide), a GLP-1 drug already shown to lower heart risk.

A heart attack, stroke or heart-related death occurred in 12.2% of people on tirzepatide and 13.1% on dulaglutide ^[10]. Tirzepatide was at least as good as dulaglutide, but it was not proven better ^{[2, 10]}.

[EXPERT QUOTE SLOT: named endocrinologist or obesity medicine physician, on why one brand's trial results describe the same molecule but not the other brand's approved use. Obtain directly and log with date. Do not invent.]

Are Zepbound® and Mounjaro® side effects the same?

Yes, Zepbound® and Mounjaro® share the same side effects and warnings, because they are the same drug ^{[1, 2]}. Stomach and gut effects are the most common, mostly while the dose is being raised.

Table: Common stomach side effects on each label. Source: Zepbound® Prescribing Information, Table 1, pooled weight trials ^[1]; Mounjaro® Prescribing Information, Table 1, pooled placebo-controlled adult trials ^[2]. The trials enrolled different people, so the columns can't be compared head to head.

The rates differ because the trials differ, not because the drug differs. Zepbound®'s trials enrolled adults with obesity, mostly without diabetes, while Mounjaro®'s enrolled adults with type 2 diabetes ^{[1, 2]}.

Each label also lists a few other common side effects:

• Zepbound®: Injection site reactions, tiredness, allergic reactions, burping, hair loss and acid reflux ^[1]. The label links hair loss to weight reduction, at 4% to 5% vs. 1% on placebo.
• Mounjaro®: Decreased appetite, in 5% to 11% of people vs. 1% on placebo ^[2].

In SURMOUNT-1, side effects led 4.3% to 7.1% of people on tirzepatide to stop treatment, vs. 2.6% on placebo ^[6].

What is the boxed warning?

Both labels carry a boxed warning: tirzepatide caused thyroid C-cell tumors in rats ^{[1, 2]}. It's unknown whether it causes these tumors in humans, including medullary thyroid cancer (MTC).

Don't use either brand if you or a family member has had MTC. Don't use it if you have multiple endocrine neoplasia syndrome type 2 (MEN 2), a rare inherited condition ^{[1, 2]}.

What other serious risks are on both labels?

Both labels list the same serious risks ^{[1, 2]}:

• Pancreatitis: Inflammation of the pancreas. Stop the drug and get care if it's suspected.
• Gallbladder disease: Including gallstones.
• Kidney injury: From dehydration caused by vomiting or diarrhea.
• Severe stomach and gut reactions: Neither brand is recommended with severe gastroparesis (very slow stomach emptying).
• Low blood sugar: Risk rises with insulin or sulfonylureas.
• Serious allergic reactions: Including anaphylaxis and swelling of the face or throat.
• Diabetic eye disease: Monitoring is advised for people with type 2 diabetes and a history of diabetic retinopathy.
• Aspiration during anesthesia: Tell your surgical team you take tirzepatide before any procedure.

Birth control pills: Tirzepatide can make oral birth control less effective ^{[1, 2]}. Both labels advise switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and after each dose increase.

One label difference is worth noting. In February 2026, Zepbound®'s label removed its separate warning on suicidal behavior and ideation ^[1]. New or worse depression, or thoughts of self-harm, on any medicine still need prompt care.

Can you use Mounjaro® for weight loss?

Mounjaro® is not FDA-approved for weight loss, so using it for weight is off-label ^[2]. A prescriber can legally prescribe it that way, but insurers usually won't cover it without a type 2 diabetes diagnosis.

Off-label use does happen. "Off label use" appears in 7,811 FAERS reports for Mounjaro® as of July 30, 2026 ^[14].

For adults without diabetes, off-label use is rarely needed, because Zepbound® carries the weight approval ^[1]. The molecule and doses are the same, so the usual reason to choose Mounjaro® for weight is coverage or supply, not results.

Can you switch from Mounjaro® to Zepbound®?

Yes, you can switch from Mounjaro® to Zepbound®, or back, with a new prescription. Here's how a switch usually works:

• Your prescriber decides whether a switch makes sense, often because your diagnosis or insurance changed.
• Your prescriber picks the dose. The strengths match, so a similar dose can often continue, but that call is theirs.
• Your plan may need new paperwork, such as a prior authorization tied to the new brand's approved use.
• You get training if the new brand comes in a different form, such as a vial instead of a pen ^{[1, 2]}.

Don't overlap the two brands during a switch. Stop one when you start the other, on the schedule your prescriber gives you.

Can you take Zepbound® and Mounjaro® together?

No, Zepbound® and Mounjaro® should not be taken together. Zepbound®'s label says not to use it with any other tirzepatide product or any GLP-1 receptor agonist ^[1]. Taking both would double the same drug and raise the risk of side effects.

That also rules out pairing tirzepatide with:

• Ozempic® or Wegovy® (semaglutide)
• Trulicity® (dulaglutide)
• Compounded or "research" tirzepatide or semaglutide

Some pairings are allowed with care. Mounjaro® can be used with metformin and with insulin, given as separate injections and never mixed in one syringe ^[2]. Your prescriber may lower an insulin or sulfonylurea dose to prevent low blood sugar ^{[1, 2]}.

Tirzepatide slows stomach emptying, which can change how pills are absorbed ^{[1, 2]}. Tell your prescriber and pharmacist about every medicine you take, including blood thinners such as warfarin.

Related reading

• Zepbound® side effects: what to expect and how long they last: tips for nausea during dose increases [LINK: verify live]
• Mounjaro® dosage guide: how each step up works, per the label [LINK: verify live]
• Tirzepatide vs. semaglutide: how the two molecules compare in trials [LINK: verify live]
• Weight loss treatment options: every approved option in one place [LINK: verify live]

Does insurance or Medicare cover Zepbound® and Mounjaro®?

Insurance coverage for Zepbound® and Mounjaro® follows the diagnosis, not the molecule. Plans usually cover a brand only for the uses on its label, so type 2 diabetes points to Mounjaro®, and obesity or sleep apnea points to Zepbound®.

Many plans require prior authorization, which is pre-approval paperwork from your prescriber. Coverage rules and out-of-pocket costs vary by plan and by form.

Table: Medicare coverage paths by diagnosis. Source: CMS, Medicare GLP-1 Bridge ^[11]; Medicare.gov, Weight loss drugs ^[12], both retrieved October 2, 2026.

Standard Medicare Part D still can't cover drugs used only for weight loss. The Medicare GLP-1 Bridge is a temporary CMS program that covers certain GLP-1 drugs for weight outside the usual Part D benefit ^[11].

The Bridge covers the Zepbound® KwikPen only, not single-dose Zepbound® vials or pens ^[12]. To qualify, you must be 18 or older and meet a BMI and health-condition rule, such as a BMI of 35 or higher ^[12].

People with type 2 diabetes or moderate to severe sleep apnea aren't eligible for the Bridge, since their Part D plan may already cover a GLP-1 ^[12]. Your prescriber must request prior authorization and certify that you're in a diet and exercise program ^[12].

Who should use Zepbound®, and who should use Mounjaro®?

Zepbound® fits adults whose main goal is weight reduction or treating sleep apnea, while Mounjaro® fits people 10 and older with type 2 diabetes ^{[1, 2]}.

Zepbound® may fit you if:

• You have obesity: A BMI of 30 or higher ^[4].
• You have overweight plus a weight-related condition: A BMI of 27 or higher with a condition such as high blood pressure, high cholesterol or heart disease ^[4].
• You have moderate to severe sleep apnea and obesity ^{[1, 5]}.

Mounjaro® may fit you if:

• You have type 2 diabetes and need better blood sugar control, as an adult or a child 10 or older ^[2].
• You have type 2 diabetes and a high risk of heart events, where lowering that risk is part of the goal ^[2].

Neither brand is right if:

• You or a family member has had medullary thyroid cancer, or you have MEN 2 ^{[1, 2]}.
• You've had a serious allergic reaction to tirzepatide ^{[1, 2]}.
• You're pregnant or planning a pregnancy: Animal studies suggest tirzepatide may harm a developing baby, so talk with your prescriber first ^{[1, 2]}.

Zepbound® isn't approved for anyone under 18 ^[1]. Neither brand is approved for type 1 diabetes.

Is compounded or "research" tirzepatide the same?

No, compounded tirzepatide is not the same as Zepbound® or Mounjaro®. Compounded tirzepatide is not FDA-approved, and it isn't a generic version of either brand. The FDA doesn't review compounded drugs for safety, effectiveness or quality, and the trial results above come from Zepbound® and Mounjaro® themselves ^[13].

There is no generic tirzepatide in the U.S. The FDA says compounded GLP-1 drugs should only be used when a patient's needs can't be met by an approved drug ^[13].

The FDA also lists red flags for online sellers ^[13]:

• Same-as claims: The seller says a compounded drug is the same as an approved one.
• No real screening: No licensed prescriber reviews your health before selling.
• Odd products: The medicine looks different from before, or arrives damaged or without instructions.
• Too-good deals: Discounts that seem too good to be true.

Tirzepatide sold online "for research use only" is more dangerous still. It isn't made for people, and it may contain the wrong substance, no drug at all or contaminants. Don't inject it.

When should you see a healthcare provider?

See your prescriber before starting, switching or stopping Zepbound® or Mounjaro®, and any time side effects keep you from eating or drinking. Ongoing vomiting or diarrhea can dehydrate you and harm your kidneys ^{[1, 2]}.

Contact your prescriber soon if you notice:

• Neck changes: A lump or swelling in your neck, trouble swallowing, hoarseness or shortness of breath, which can be signs of a thyroid tumor ^{[1, 2]}.
• Gallbladder signs: Pain in your upper right belly, fever, yellow skin or eyes, or clay-colored stools ^{[1, 2]}.
• Vision changes: Especially if you have type 2 diabetes ^{[1, 2]}.
• Mood changes: New or worse depression or unusual changes in mood.

Call 911 or go to the nearest ER if you have any of these:

• Severe stomach pain that won't go away, with or without vomiting, which can be a sign of pancreatitis ^{[1, 2]}.
• Signs of a severe allergic reaction, such as swelling of the face, lips, tongue or throat, trouble breathing or a fast heartbeat ^{[1, 2]}.
• Signs of severe low blood sugar, such as confusion, seizures or passing out ^{[1, 2]}.
• Thoughts of harming yourself. You can also call or text 988, the Suicide and Crisis Lifeline.

Sources